patients thought to be "cured" are expected to develop a recurrence of CRC within 5 years -- usually due to undetected metastases.** Frequent surveillance of diagnosed patients is recommended, but current procedures have shortcomings. This includes the Carcinoembryonic Antigen blood test currently used for surveillance of CRC, which suffers from poor sensitivity and specificity (i.e. the ability to determine if someone actually has, or does not have, CRC). Through its study with Mayo Clinic, AMDL looks to improve upon negatives found in existing tests.
*National Cancer Institute: Cancer Facts and Figures 2008.
**Bull World Health Organ: Shike M, Winawer SJ, Greenwald PH, et al.
Headquartered in Tustin, CA with operations in China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 490 people in the U.S. and China.
About Mayo Clinic
Mayo Validation Support Services, an affiliate of Mayo Clinic, based in Rochester, Minnesota assists pharmaceutical, biotechnology and diagnostic companies in validating the clinical significance of emerging biomarkers and technologies. Mayo's contribution of well-annotated biospecimens and clinical follow-up data support the development of individualized medicine, one of Mayo's strategic initiatives.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual resulPage: 1 2 3 Related biology technology :1
. AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business Objectives2
. AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 20083
. AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team4
. AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO5
. AMDL, Inc.s President & CEO Mr. Gary Dreher Retires6
. AMDL, Inc. Named to Deloitte LLC Technology Fast 507
. AMDL, Inc. Announces Strategic Realignment8
. AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 20089
. AMDL, Inc. Closes Private Placement of Convertible Notes10
. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue11
. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance